RPID — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-15

• We generated revenue of $8.0 million and $7.2 million for the three months ended March 31, 2026 and 2025, respectively, and incurred net losses of $14.3 million and $11.3 million for those same periods, respectively.

• We believe that our cash, cash equivalents and investments as of March 31, 2026 and additional borrowing capacity expected to become under the LSA that is subject to the satisfaction of certain commercial and operational milestones and other conditions later this year enable us to fund our operating…

• In February 2025, we entered into a Distribution and Collaboration Agreement (the “Distribution Agreement”) with Millipore S.A.S., a subsidiary of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the

• U.S. as MilliporeSigma ("MilliporeSigma”). Pursuant to the Distribution Agreement, we granted MilliporeSigma a global, co-exclusive right to sell our products, initially consisting of our Growth Direct systems and related consumables, into all fields related to industrial quality control application…

• Over the first two years of the Distribution Agreement, MilliporeSigma has committed to purchase a minimum number of Growth Direct systems. Thereafter, we and MilliporeSigma will evaluate and mutually agree on additional purchase commitments, if any. Pursuant to the Distribution Agreement, we are pe…

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• Since our inception, we have incurred net losses in each year. We generated revenue of $7.8 million and $7.6 million for the three months ended September 30, 2025 and 2024, respectively, and incurred net losses of $11.5 million and $11.3 million for those same periods, respectively. As of September …

• •growing sales of our products in both the United States and international markets by further expanding our sales and marketing capabilities;

• •scaling our manufacturing and supply chain processes and infrastructure to meet growing demand for our products;

• •investing in research and development to develop new products and further enhance our existing products;

• •protecting and building on our intellectual property portfolio; and

Text added vs the prior filing · source: 10-Q · 2026-05-15

• As of March 31, 2026, we had cash, cash equivalents and short-term investments of $23.2 million, which consisted of cash, money market funds, U.S. treasury bills, and U.S. treasury notes. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of th…

• We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.

• While we have experienced some impact from inflation related mainly to our materials, labor and freight costs, we have been able to mitigate further impacts, including through long-term contracts and commitments with key suppliers. In addition, we continue to monitor the impact of inflation on these…

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and infla…

Text added vs the prior filing · source: 10-Q · 2026-05-15

• evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer to allow timely decisions regarding required disclosures. Based on that evaluation, our principal executive officer …

Text added vs the prior filing · source: 10-Q · 2026-05-15

• Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. For example, while we have experienced positive trends in our gross margin percentage, expansio…

• Our actual business results may vary significantly from such guidance due to a number of factors, many of which are outside of our control, including our customers’ demand for our Growth Direct systems, the length of the sales cycle for purchases of our systems, customer site readiness and the lead …

• which have in the past and may in the future adversely affect our business and operating results. For example, guidance that we provide is based on system purchase order commitments that we have in hand or expect to receive in the future, which may not be a reliable indicator. We recognize revenue u…

• The LSA contains customary covenants that could prevent us from taking certain actions without the consent of the Lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders. For additional informa…

• renegotiate our agreement on terms less favorable to us or to immediately cease operations. Any declaration by the Lenders of an event of default would therefore significantly harm our business and prospects and could cause the price of our common stock to decline.

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. For example, we have experienced positive trends in our gross margins, improving from (5)% to 6…

• variability from period to period. Additionally, revenue growth and operating expenses may also be subject to variability from period to period. For example, we recently raised guidance with respect to Growth Direct system placements and total revenue for the full year ending December 31, 2025, toge…

• Our actual business results may vary significantly from such guidance due to a number of factors, many of which are outside of our control, including our customers’ demand for our Growth Direct systems, the length of the sales cycle for purchases of our systems, customer site readiness and the lead …

• of our systems, or if our existing customers decide to purchase fewer of our consumables and service contracts or terminate their relationships with us, our revenue could significantly decrease, which would have an adverse effect on our financial condition and results of operations and could adverse…

• The LSA contains customary affirmative and negative covenants that could prevent us from taking certain actions without the consent of the Lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholder…

Text added vs the prior filing · source: 10-Q · 2026-05-15

• On March 16, 2026, Robert Spignesi, President, Chief Executive Officer and Director, terminated a 10b5-1 trading plan that he entered into on December 17, 2025 (the “Prior Spignesi 10b5-1 Trading Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and provided fo…

• On March 17, 2026, Robert Spignesi, President, Chief Executive Officer and Director, adopted a new 10b5-1 trading plan (the “Spignesi 10b5-1 Trading Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of expiring vested st…

• None of our other directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement, or adopted, modified or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended March 31, 2026.

Text removed vs the prior filing · source: 10-Q · 2025-11-07

• None of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement, or adopted, modified or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended September 30, 2025.